Solving COVID: December 2, 2020
The U.K. approves a COVID-19 vaccine, Moderna says its vaccine candidate prevents severe illness, and more

- 1. U.K. approves Pfizer-BioNTech COVID-19 vaccine for widespread emergency use, starting next week
- 2. Moderna says its COVID-19 vaccine is 100 percent effective at preventing severe cases
- 3. FDA approves test designed to measure specific COVID-19 antibody levels
- 4. CDC advisory panel recommends long-term care residents, health-care workers receive vaccine first
- 5. Director of global pharma group anticipates as many as 10 COVID-19 vaccines by 2021
1. U.K. approves Pfizer-BioNTech COVID-19 vaccine for widespread emergency use, starting next week
Britain's medicine and health-care regulator, the MHRA, gave emergency approval Wednesday for the COVID-19 vaccine made by Pfizer and BioNTech, making the U.K. the first country to green-light the promising vaccine for mass rollout. Britain has already ordered 40 million doses of the vaccine, or enough to inoculate 20 million people, and the first doses should arrive in the coming days. "Help is on its way," Health Secretary Matt Hancock tweeted: "The NHS stands ready to start vaccinating early next week." Pfizer and Moderna have both reported a 95 percent effectiveness rate for their vaccines from large human clinical trials. The U.S. Food and Drug Administration is expected to grant such authorization for both vaccines in the next two or three weeks.
2. Moderna says its COVID-19 vaccine is 100 percent effective at preventing severe cases
All but 11 of the 196 Moderna COVID-19 vaccine trial participants who contracted the virus were in the placebo group, good for a 94 percent efficacy rate. But, perhaps even more crucially, none of the people who received the vaccine developed a severe infection, the company said. There were 30 severe cases — including one death — in the trial, but all of those occurred in the placebo group. Experts have previously highlighted the importance of companies separating out the worst cases in vaccine trials, arguing that a candidate's true efficacy should be determined by its ability to protect against severe infections. It appears Moderna has done just that.
Subscribe to The Week
Escape your echo chamber. Get the facts behind the news, plus analysis from multiple perspectives.

Sign up for The Week's Free Newsletters
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
The Associated Press The New York Times
3. FDA approves test designed to measure specific COVID-19 antibody levels
The Food and Drug Administration approved a "new generation" of COVID-19 antibody test designed to detect how well people are protected against subsequent infection. Most antibody tests are able to tell whether a person has contracted the virus or not, and some can estimate the level of neutralizing antibodies someone has, CNBC notes. But the newly-authorized COVID-SeroKlir developed by Kantaro BioSciences measures specific levels. The catch is that scientists aren't sure if high levels of antibodies guarantee COVID-19 immunity, so the test won't necessarily serve as proof that someone is protected against re-infection. What it will do, however, is allow researchers to gain a better understanding of the correlation between antibody levels and immunity, which will come in handy both for people who have been exposed to the virus already and for vaccine development.
4. CDC advisory panel recommends long-term care residents, health-care workers receive vaccine first
The Centers for Disease Control and Prevention will advise that health-care workers and long-term care facility residents receive COVID-19 vaccinations first, if and when Food and Drug Administration approval is granted. The decision was reached by the Advisory Committee on Immunization Practices, which is advising the CDC on vaccine distribution practices. As vaccine approval for emergency use becomes increasingly likely in the coming weeks, the panel voted 13-1 in favor of a motion elevating two groups to the front of the line. Health-care workers are frequently exposed to the virus and are essential to keeping hospitals running throughout the pandemic, while nursing homes have faced some of the deadliest COVID-19 outbreaks across the country.
Sign up for Today's Best Articles in your inbox
A free daily email with the biggest news stories of the day – and the best features from TheWeek.com
5. Director of global pharma group anticipates as many as 10 COVID-19 vaccines by 2021
Thomas Cueni, the director-general of the International Federation of Pharmaceutical Manufacturers and Associations, said that as many as 10 COVID-19 vaccines could be available by the middle of next year, as long as they are granted approval by regulatory agencies. Cueni noted that the vaccine developers that have already released info from late-stage trials — Pfizer and BioNTech, Moderna, and the University of Oxford and AstraZeneca — have all showed promising results (although the latter is amending its trial after confusing results), and he expects similar data from Johnson & Johnson, Novavax, Sanofi Pasteur, GSK, and Merck. "But all of them need to be submitted by rigorous scientific scrutiny by the regulators," he said.
-
Mario Vargas Llosa: The novelist who lectured Latin America
Feature The Peruvian novelist wove tales of political corruption and moral compromise
By The Week US
-
How to see the Lyrid meteor shower
The explainer A nice time to look to the skies
By Devika Rao, The Week US
-
Climate: Trump's attempt to bring back coal
Feature Trump rolls back climate policies with executive orders aimed at reviving the coal industry
By The Week US
-
Why Russia removed the Taliban's terrorist designation
The Explainer Russia had designated the Taliban as a terrorist group over 20 years ago
By Justin Klawans, The Week US
-
Inside the Israel-Turkey geopolitical dance across Syria
THE EXPLAINER As Syria struggles in the wake of the Assad regime's collapse, its neighbors are carefully coordinating to avoid potential military confrontations
By Rafi Schwartz, The Week US
-
'Like a sound from hell': Serbia and sonic weapons
The Explainer Half a million people sign petition alleging Serbian police used an illegal 'sound cannon' to disrupt anti-government protests
By Abby Wilson
-
The arrest of the Philippines' former president leaves the country's drug war in disarray
In the Spotlight Rodrigo Duterte was arrested by the ICC earlier this month
By Justin Klawans, The Week US
-
Ukrainian election: who could replace Zelenskyy?
The Explainer Donald Trump's 'dictator' jibe raises pressure on Ukraine to the polls while the country is under martial law
By Sorcha Bradley, The Week UK
-
Why Serbian protesters set off smoke bombs in parliament
THE EXPLAINER Ongoing anti-corruption protests erupted into full view this week as Serbian protesters threw the country's legislature into chaos
By Rafi Schwartz, The Week US
-
Who is the Hat Man? 'Shadow people' and sleep paralysis
In Depth 'Sleep demons' have plagued our dreams throughout the centuries, but the explanation could be medical
By The Week Staff
-
Why Assad fell so fast
The Explainer The newly liberated Syria is in an incredibly precarious position, but it's too soon to succumb to defeatist gloom
By The Week UK